IMPACT OF THE PEGYLATED-INTERFERON AND RIBAVIRIN THERAPY ON THE TREATMENT-RELATED MORTALITY OF PATIENTS WITH CIRRHOSIS DUE TO HEPATITIS C VIRUS

Although the protease inhibitors have revolutionized the therapy of chronic hepatitis C (CHC), the concomitant use of pegylated-interferon (PEG-IFN) and ribavirin (RBV) is associated to a high rate of adverse effects. In this study, we evaluated the consequences of PEG-IFN and RBV and their relation...

Descripción completa

Detalles Bibliográficos
Autores principales: DRESCH, Kelly Fernanda Nomura, de MATTOS, Angelo Alves, TOVO, Cristiane Valle, de ONOFRIO, Fernanda Quadros, CASAGRANDE, Leandro, FELTRIN, Alberi Adolfo, de BARROS, Iago Christofoli, de ALMEIDA, Paulo Roberto Lerias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Instituto de Medicina Tropical 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879994/
https://www.ncbi.nlm.nih.gov/pubmed/27253739
http://dx.doi.org/10.1590/S1678-9946201658037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879994/
https://www.ncbi.nlm.nih.gov/pubmed/27253739
http://dx.doi.org/10.1590/S1678-9946201658037

Ejemplares similares